Parminder Judge
Overview
Explore the profile of Parminder Judge including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
653
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Herrington W, Staplin N, Agrawal N, Wanner C, Green J, Hauske S, et al.
N Engl J Med
. 2024 Oct;
392(8):777-787.
PMID: 39453837
Background: In the EMPA-KIDNEY trial, empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, had positive cardiorenal effects in patients with chronic kidney disease who were at risk for disease progression. Post-trial...
2.
Herrington W, Staplin N, Wanner C, Green J, Hauske S, Emberson J, et al.
N Engl J Med
. 2022 Nov;
388(2):117-127.
PMID: 36331190
Background: The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the...
3.
Herrington W, Illingworth N, Staplin N, Kumar A, Storey B, Hrusecka R, et al.
Clin J Am Soc Nephrol
. 2016 Sep;
11(10):1794-1801.
PMID: 27654930
Background And Objectives: Because there is substantial biologic intraindividual variation in albumin excretion, randomized trials of albuminuria-reducing therapies may need multiple urine samples to estimate daily urinary albumin excretion. Mailing...
4.
Gross O, Kashtan C, Rheault M, Flinter F, Savige J, Miner J, et al.
Nephrol Dial Transplant
. 2016 May;
32(6):916-924.
PMID: 27190345
Alport syndrome (AS) is a genetic disease characterized by haematuric glomerulopathy variably associated with hearing loss and anterior lenticonus. It is caused by mutations in the COL4A3, COL4A4 or COL4A5...
5.
Judge P, Haynes R, Landray M, Baigent C
Nephrol Dial Transplant
. 2014 Aug;
30(5):738-43.
PMID: 25140014
Despite current practice, patients with chronic kidney disease (CKD) are at increased risk of progression to end-stage renal disease and cardiovascular events. Neprilysin inhibition (NEPi) is a new therapeutic strategy...
6.
Haynes R, Harden P, Judge P, Blackwell L, Emberson J, Landray M, et al.
Lancet
. 2014 Aug;
384(9955):1684-90.
PMID: 25078310
Background: Calcineurin inhibitors (CNIs) reduce short-term kidney transplant failure, but might contribute to transplant failure in the long-term. The role of alemtuzumab (a potent lymphocyte-depleting antibody) as an induction treatment...
7.
Miner J, Baigent C, Flinter F, Gross O, Judge P, Kashtan C, et al.
Kidney Int
. 2014 Jul;
86(4):679-84.
PMID: 24988067
Alport syndrome, historically referred to as hereditary glomerulonephritis with sensorineural deafness and anterior lenticonus, is a genetic disease of collagen α3α4α5(IV) resulting in renal failure. The collagen α3α4α5(IV) heterotrimer forms...